Clinical Trial Details
— Status: Active, not recruiting
Administrative data
| NCT number |
NCT05511688 |
| Other study ID # |
Colomin2 Cohort |
| Secondary ID |
|
| Status |
Active, not recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
March 22, 2017 |
| Est. completion date |
October 2022 |
Study information
| Verified date |
August 2022 |
| Source |
Federation Francophone de Cancerologie Digestive |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
The three main pathways of colorectal carcinogenesis are chromosomal instability,
microsatellite instability (MSI) (15% of colorectal cancers =CRCs) and CpG island methylator
phenotype (CIMP). MSI CRCs are associated with a better prognosis after curative surgery than
CRCs without microsatellite instability (MSS). In contrast, MSI CRCs do not appear to benefit
from adjuvant 5-FU chemotherapy, unlike patients with MSS CRCs. Nevertheless, the benefit of
adjuvant chemotherapy with FOLFOX seems to be retained. The identification of prognostic
markers in this subgroup of patients is therefore essential to decide on adjuvant
chemotherapy, the efficacy of which is currently debated in MSI CRC.
To date, there are very few data concerning metastatic MSI CRC. Metastatic forms are rare
(about 5% of metastatic CRCs), but are thought to be associated with chemoresistance and poor
prognosis. Nevertheless, data are very sparse and there are no data regarding the use of
modern chemotherapies and targeted therapies in metastatic MSI CRC. Thus, it is important to
characterize the chemosensitivity of metastatic forms.
Clinical predictors of recurrence after curative CRC surgery are known but have only been
studied in MSI CRC retrospectively. Similarly, many molecular and immunohistochemical
factors, prognostic or predictive of response to adjuvant chemotherapy, have been recently
identified in CRC (KRAS, BRAF, TP53, PI3KCA mutations, CIMP phenotype, SMAD4, immune
response...). Most of these markers have been studied in all CRCs, but not specifically in
the MSI CRC subgroup. All these prognostic and/or predictive biomarkers need to be better
characterized in a large cohort of MSI CRCs.
Description:
Colorectal cancers with microsatellite instability The 3 main pathways of colorectal
carcinogenesis are chromosomal instability (75% of CRCs), microsatellite instability (15% of
CRCs) and CpG island hypermethylation or CIMP (CpG island methylator phenotype) (25% of
CRCs).
Microsatellite instability (MSI) or RER+ (replication errors) phenotype is related to an
acquired or inherited inactivation of the MMR (mismatch repair) system of DNA mismatch
repair. In MSI CRCs associated with Lynch syndrome or HNPCC (hereditary nonpolyposis
colorectal cancer) (3% of CRCs), there is a germline mutation in one of the genes of the MMR
system, essentially MLH1 or MSH2, more rarely MSH6 or PMS2. In sporadic MSI cancers,
frequently observed in the elderly, the loss of function of the MMR system is linked to a
biallelic hypermethylation of the CpG islands of the MLH1 gene promoter causing its
inactivation. Molecular individualization of CRCs has allowed the identification of tumor
subgroups, such as MSI CRCs, that are more homogeneous in terms of their progression pathway,
but the impact in terms of prognosis and treatment sensitivity remains to be clarified.
Prognosis and chemosensitivity of colorectal cancers with microsatellite instability MSI CRCs
are associated with a better prognosis after curative surgery than CRCs without
microsatellite instability (MSS) . In contrast, retrospective analyses of randomized trials
indicate that patients with MSI CRC do not appear to benefit from adjuvant 5-FU-based
chemotherapy in contrast to patients with MSS CRC. Nevertheless, the benefit of adjuvant
chemotherapy with FOLFOX seems to be retained . The identification of prognostic markers in
this subgroup of patients is therefore essential to decide on adjuvant chemotherapy, the
efficacy of which is currently debated in MSI CRC.
To date, there are very few data concerning metastatic MSI CRC. Metastatic forms are rare
(about 5% of metastatic CRCs), but are thought to be associated with chemoresistance and poor
prognosis . Nevertheless, data are very sparse and there are no data regarding the use of
modern chemotherapies and targeted therapies in metastatic MSI CRC. Thus, it is important to
characterize the chemosensitivity of metastatic forms in order to offer the best treatment to
patients.
Recent data show significant efficacy of immune checkpoint inhibitors in MSI CRC, including
anti-PD1. Indeed, these tumors present a high number of mutations generating immunogenic
neo-antigens. Thus, escape from anti-tumor immunity is a major mechanism of progression of
MSI CRCs .
Prognostic and predictive factors of response to chemotherapy in colorectal cancer with
microsatellite instability The clinical predictive factors for recurrence after curative CRC
surgery are known (lymph node involvement, T4 stage, VELIPI criteria (vascular emboli,
perineural sheaths, and lymphatic emboli), poorly differentiated tumor, analysis of fewer
than 12 nodes, tumor perforation, and overt bowel obstruction). These criteria have only been
studied in MSI CRCs retrospectively. A large French retrospective study of MSI CRCs included
521 MSI CRCs. Four independent predictors of recurrence-free survival were identified, age
(HR=1.02; 95%IC 1.00-1.04, p=0.014), initial bowel obstruction (HR=2.33; 95%CI 1.29-4.23,
p=0.005), vascular emboli (HR=2.27; 95%IC 1.41-3.63, p<0.001), and stage T4 (HR=2.09; 95%IC
1.28-3.40, p=0.003). It should be noted that, unlike MSS CRCs, the prognostic impact of lymph
node involvement appears to be small. This work is nevertheless limited by missing data
(5-30%), biases related to retrospective analysis and the absence of exploitable molecular
analyses (notably KRAS and BRAF mutation). These data can be validated prospectively from the
COLOMIN 2 cohort.
In stage III MSI CRC, adjuvant chemotherapy with FOLFOX is recommended. On the other hand, in
stage II MSI CRC, simple surveillance is recommended given the good prognosis . Nevertheless,
in case of vascular emboli and/or T4 stage in MSI stage II CRC, the risk of recurrence
becomes clinically significant (more than 20% at 2 years) and therefore raises the question
of adjuvant treatment on a case-by-case basis. Indeed, in high-risk stage II MSI CRC, FOLFOX
seems to provide a benefit in terms of recurrence-free survival compared with surgery alone .
The COLOMIN 2 cohort will allow prospective confirmation of the chemosensitivity of these
tumors to oxaliplatin.
Many molecular and immunohistochemical factors, prognostic or predictive of response to
adjuvant chemotherapy, have been recently identified in CRC (KRAS, BRAF, TP53, PI3KCA
mutations, CIMP phenotype, SMAD4, immune response...). These markers have been mostly studied
in all CRCs, but not specifically in the subgroup of MSI CRCs. All these molecular and
immunohistochemical factors need to be better characterized in a large cohort of MSI CRCs in
order to determine their exact frequencies, their associations with each other, their
prognostic and predictive values of response to chemotherapy. The constitution of a
biological collection in COLOMIN 2 will allow the analysis of different biomarkers. For
example, the BRAF mutation (V600E) is associated with a poor prognosis in CRC. Nevertheless,
its prognostic impact remains debated in MSI CRC, whereas more than 50% of MSI CRC are BRAF
mutated. COLOMIN 2 will assess the prognostic impact of BRAF mutation in MSI CRC.
